B
Bone Biologics Corporation (BBLG)
NCM – Real Time Price. Currency in USD
1.40
+0.06 (4.48%)
At close: Jun 26, 2026, 4:00 PM EDT
1.39
-0.01 (-0.58%)
After-hours: Jun 26, 2026, 7:27 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.40
+0.06 (4.48%)
At close: Jun 26, 2026, 4:00 PM EDT
1.39
-0.01 (-0.58%)
After-hours: Jun 26, 2026, 7:27 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Cash reserves $4.5M barely cover the upcoming debt maturities $0.0
Total current assets $5.0M exceed Total current liabilities $309.4K, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is near the industry average, reflecting balanced leverage
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$804.3K limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 16.09 | 6.05 | 10 | |
| Quick ratio | 16.09 | 5.63 | 10 | |
| Debt to Equity | 0.00 | 0.30 | 10 | |
| Debt to Assets | 0.00 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Operating Income | -4M | -9M | -4M | -3M | -3M |
| Net Income | -1M | -9M | -4M | -3M | -3M |
| EBITDA | -4M | -9M | -4M | -3M | -3M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 70.68 | 5.5 |
| Next quarter | N/A | 2.7 | 2.5 |
| Current year | N/A | 42.64 | 5.5 |
| Next year | N/A | 17.11 | 5.0 |
| Weighted average score | 4.6 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -11.87 | 25.86 | -12.51 | 5.5 |
| Y/Y | 999 | 24.69 | -34.37 | 13.16 | 7.3 |
| 3y average | 999 | -141.43 | N/A | -25.42 | 3.3 |
| 5y average | 999 | -80.94 | N/A | -90.87 | 3.3 |
| Weighted average score | 4.9 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | Narrow | 2.0 |
| Intangible assets | Narrow | 3.0 |
| Switching costs | Narrow | 2.0 |
| Network effect | Narrow | 2.0 |
| Economies of scale | Narrow | 4.0 |
| Weighted average score | 2.6 | |